Growth Equity Opportunities Fund IV, LLC 13D and 13G filings for AVEO Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2022-11-01 5:01 pm Sale |
2022-10-20 | 13D | AVEO Pharmaceuticals, Inc. AVEO |
Growth Equity Opportunities Fund IV, LLC | 0 0.000% |
-5,424,009![]() (Position Closed) |
Filing |